Our lab studies the unique immunology of human brain tumors. The lab aims to translate its scientific finding into clinical investigations in the field of cancer immunotherapy.

Our lab has developed a unique approach we call "Split Immunity", to immunologically treat brain tumors. This approach has already been utilized to treat two patients in a First in human (FIH) trial. Based on the results attained, additional twelve patients will be treated as part of an approved phase I/II trial that will soon commence.

For this project and other projects in the lab, we have developed an elaborate immunological toolbox consisting of advanced multicolor flow cytometry (up to 16 colors) coupled with transcriptomic tools. The developed toolbox has recently been licensed to a company named "Pyxis Diagnostics" aimed at identifying predictive biomarkers for cancer immunotherapy.

Using the labs' approach and methodologies, we study key immune cells within brain tumors. Cells such as dendritic cells, T cells, macrophages and microglia, serve different roles within the tumor-immune network and determine the fate of natural responses to the tumor as well as those responses induced by immunotherapyץ

See our website for details on current projects run in our lab.